James R. Johnson, MD
This content is PDF only. Please click on the PDF icon to access.
To the editors: Uncritical clinical application of the T-cell proliferative assay described by Dressier and colleagues (1) may further confuse the evaluation of patients for Lyme disease. The investigators proposed that the test may be helpful in evaluating patients who have clinically apparent late-stage Lyme disease and whose humoral immune response has waned or has been aborted by early (subcurative) antibiotic therapy (1). Such circumstances are rarely encountered. Furthermore, the need for a confirmatory diagnostic test is arguable; few physicians would withhold antimicrobial therapy for Lyme disease on the basis of seronegativity when the patient's history and physical findings are
Johnson JR. Diagnosing Lyme Disease. Ann Intern Med. 1992;116:603. doi: https://doi.org/10.7326/0003-4819-116-7-603_1
Download citation file:
Published: Ann Intern Med. 1992;116(7):603.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use